Having recently raised $6.1m in a funding round, Biotech company Pictor has now obtained CE mark for its PictArray SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) antibody test.

The approval will enable the firm to market the antibody test in Europe and obtain regulatory approval in South East Asian markets.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Claimed to be the first of its kind, the PictArray SARS-CoV-2 ELISA antibody test is designed to separately identify antibodies from vaccines and Covid-19 infection in a single test.

It detects whether a patient has antibodies from a previous SARS-CoV-2 infection (from spike protein (SP) and nucleocapsid protein (NP) antibodies) or from vaccination alone (SP antibodies only).

Pictor chief medical officer Tadd Lazarus said: “As we learn more about Covid-19, the separate detection of SP and NP will enable a more precise assessment of a patient’s immunity against SARS-CoV-2 and help guide any associated clinical interventions whilst also informing wider public health measures when mass serosurveys are conducted.”

Furthermore, the PictArray Covid-19 antibody test enables personalised Covid-19 assessments and will indicate whether patients require a Covid-19 booster.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It also helps identify at-risk patients who do not have a detectable antibody response to SARS-CoV-2, despite being previously vaccinated or infected.

Pictor CEO Howard Moore said: “Receiving CE registration enables Pictor to establish a footprint with partner laboratories and research bodies within Europe which is an important market for us.

“Our recent successful funding round means we are well equipped to support market development and launches within the European Economic Area while continuing existing work across Australia and New Zealand (ANZ), the US, India and South East Asia.”

In April, the company partnered with Mobility Health to launch the PictArray SARS-CoV-2 assay.